title: Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.
abstract: BACKGROUND
  Most women receiving systemic therapy for breast cancer experience hot flashes. We undertook a randomised, double-blind, placebo-controlled, multi-institutional trial to assess the efficacy of gabapentin in controlling hot flashes in women with breast cancer.
  
  
  METHODS
  420 women with breast cancer who were having two or more hot flashes per day were randomly assigned placebo, gabapentin 300 mg/day, or gabapentin 900 mg/day by mouth in three divided doses for 8 weeks. Each patient kept a 1-week, self-report diary on the frequency, severity, and duration of hot flashes before the start of the study and during weeks 4 and 8 of treatment. Analyses were by intention to treat.
  
  
  RESULTS
  Evaluable data were available on 371 participants at 4 weeks (119 placebo, 123 gabapentin 300 mg, and 129 gabapentin 900 mg) and 347 at 8 weeks (113 placebo, 114 gabapentin 300 mg, and 120 gabapentin 900 mg). The percentage decreases in hot-flash severity score between baseline and weeks 4 and 8, respectively were: 21% (95% CI 12 to 30) and 15% (1 to 29) in the placebo group; 33% (23 to 43) and 31% (16 to 46) in the group assigned gabapentin 300 mg; and 49% (42 to 56) and 46% (34 to 58) in the group assigned gabapentin 900 mg. The differences between the groups were significant (p=0.0001 at 4 weeks and p=0.007 at 8 weeks by ANCOVA for overall treatment effect, adjusted for baseline values); only the higher dose of gabapentin was associated with significant decreases in hot-flash frequency and severity.
  
  
  CONCLUSIONS
  Gabapentin is effective in the control of hot flashes at a dose of 900 mg/day, but not at a dose of 300 mg/day. This drug should be considered for treatment of hot flashes in women with breast cancer.
authors.affiliation: University of Rochester Cancer Center Community Clinical Oncology Program Research Base, University of Rochester Cancer Center, Rochester, NY 14642, USA. Kishan_Pandya@urmc.rochester.edu
authors.forename: Kishan J
authors.initials: KJ
authors.lastname: Pandya
authors.forename: Gary R
authors.initials: GR
authors.lastname: Morrow
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Roscoe
authors.forename: Hongwei
authors.initials: H
authors.lastname: Zhao
authors.forename: Jane T
authors.initials: JT
authors.lastname: Hickok
authors.forename: Eduardo
authors.initials: E
authors.lastname: Pajon
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Sweeney
authors.forename: Tarit K
authors.initials: TK
authors.lastname: Banerjee
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Flynn
mesh_terms: D000588:Amines / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications*; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D000077206:Gabapentin; D019584:Hot Flashes / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin